Stereological Analysis on Migration of Human Neural Stem Cells in the Brain of Rats Bearing Glioma

Kim, Jae Ho; Lee, Jong Eun; Kim, Seung Up; Cho, Kyung Gi

doi:10.1227/01.neu.0000363720.07070.a8

Cited by 29 publications

(26 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intracranial medulloblastoma [ 45 ] Leptomeningeal medulloblastoma [ 46 ] Brainstem glioma [ 47 ] Brain metastasis from melanoma [ 49 ] Brain metastasis from breast cancer [ 50 ] Syngenic GBM With stereological and histological examination of tumor bearing rodent models, HB1.F3 cells were reported to be extremely migratory towards main tumor mass as well as distant tumor deposits [ 21 ]. Similarly, using confocal microscopy and mathematical modeling, the tumor-centric distribution of DiI-labeled HB1.F3 cells was demonstrated in a mouse model of orthotopic glioma [ 22 ].…”

Section: Retroviral Transductionmentioning

confidence: 98%

Neural Stem Cells as Therapeutic Delivery Vehicles for Malignant Brain Tumors

Bagcı-Önder

2013

Stem Cells: Current Challenges and New Directions

View full text Add to dashboard Cite

Malignant brain tumors are nearly untreatable due to their highly infi ltrative nature and resistance to existing therapies. The main reason for recurrent tumor growth is believed to be the presence of tumor cells that migrate great distances into the brain tissue. In addition, poor delivery of therapeutics to the tumors due to blood-brain barrier limits the clinical success of currently available systemically delivered antitumor therapies. Recently, a different mode of therapeutic delivery, whereby therapeutic biomolecules are expressed by tumor-tropic neural stem cells (NSCs), has gained considerable attention. Exploiting the intrinsic tumor-homing ability of NSCs, the past decade has witnessed signifi cant advances in the discovery and development of NSC-based therapies for malignant brain tumors. Prodrug converting enzymes, immunomodulatory cytokines, pro-apoptotic (tumouricidal) agents, growth-inhibiting factors, anti-angiogenic agents, and viral particles have been among the most commonly studied antitherapeutic molecules produced by NSCs. While the mechanisms of tumor-directed NSC migration and fate of NSCs after engrafting are still not truly understood, the results from current preclinical tumor models have demonstrated promising utility for NSCs as "armed vehicles" in treatment of aggressive brain tumors. Indeed, the fi rst clinical trial with NSCdelivered antitumor agents is now in progress for recurrent gliomas.

show abstract

Section: Retroviral Transductionmentioning

confidence: 98%

Neural Stem Cells as Therapeutic Delivery Vehicles for Malignant Brain Tumors

Bagcı-Önder

2013

Stem Cells: Current Challenges and New Directions

View full text Add to dashboard Cite

show abstract

“…The rate and pattern of NSC migration to the tumor mass in vivo has been recently described [18]. After NSC injection, about 10% of NSC migrated into the tumour mass by 50 minutes.…”

Section: Biological Properties Of the Cell Vehiclementioning

confidence: 99%

“…The rate of NSC migration was approximately 175 microm/min. In the absence of tumor, the injected NSC increased in number approximately 1.7-fold during the first day but their proliferation began to decline at the sixth day after injection [18]. Labeling with ferumoxide-protamine sulfate complex (FE-Pro) has been proposed for real-time tracking of NSC in clinical trials.…”

Section: Biological Properties Of the Cell Vehiclementioning

confidence: 99%

Stem Cell-Mediated Delivery of Therapies in the Treatment of Glioma

Fròsina

2011

MRMC

View full text Add to dashboard Cite

High grade gliomas can be seldom controlled, due to the infiltrative nature of these tumors and the presence of cell populations resistant to radio- and chemotherapy. Current research aims to develop novel therapeutic approaches to track and eliminate the disseminated glioma-driving cells. Selected delivery of therapeutic agents taking advantage of the tropism of normal stem cells for glioma cells might be one.

show abstract

“…F3 (human) [50,51], bone marrow-derived neural progenitor stem cells (murine) [52], primary murine NSC [53], and HNT2RA2 (human) [54]. The number of GBM cell lines used for these studies are large and include murine cell lines such as GL261 [53], RG2 [52], C6 [55], and CNS-1 [6] as well as the human cell lines U87 [54], U-373 [50] and U251 [56]. Additionally, new invasive patient-derived GBM lines are allowing investigations into the ability of NSCs to track GBM cells as they invade the brain parenchyma [57,58].…”

Section: Homingmentioning

confidence: 99%

Neural stem cell therapy for cancer

Bagó

Sheets

Hingtgen

2016

Methods

View full text Add to dashboard Cite

Cancers of the brain remain one of the greatest medical challenges. Traditional surgery and chemoradiation therapy are unable to eradicate diffuse cancer cells and tumor recurrence is nearly inevitable. In contrast to traditional regenerative medicine applications, engineered neural stem cells (NSCs) are emerging as a promising new therapeutic strategy for cancer therapy. The tumor-homing properties allow NSCs to access both primary and invasive tumor foci, creating a novel delivery platform. NSCs engineered with a wide array of cytotoxic agents have been found to significantly reduce tumor volumes and markedly extend survival in preclinical models. With the recent launch of new clinical trials, the potential to successfully manage cancer in human patients with cytotoxic NSC therapy is moving closer to becoming a reality.

show abstract

Stereological Analysis on Migration of Human Neural Stem Cells in the Brain of Rats Bearing Glioma

Cited by 29 publications

References 38 publications

Neural Stem Cells as Therapeutic Delivery Vehicles for Malignant Brain Tumors

Neural Stem Cells as Therapeutic Delivery Vehicles for Malignant Brain Tumors

Stem Cell-Mediated Delivery of Therapies in the Treatment of Glioma

Neural stem cell therapy for cancer

Contact Info

Product

Resources

About